Key Takeaways from the Microbiome Competitive Landscape Report
-
Over 130+ companies and 180+ pipeline drugs in Microbiome Competitive landscape.
-
Leading Microbiome companies developing novel drug candidates to improve the Microbiome treatment landscape include Ferring Pharmaceuticals, Miyarisan Pharmaceutical, Seres Therapeutics, 4D Pharma, Caelus Health, MRM Health, Scioto Biosciences, Adiso Therapeutics, and many others.
-
Servatus Biopharmaceuticals
-
Promising PD-1 and PD-L1 Inhibitors pipeline therapies in various stages of development include RBX 2660, SER-109, Blautix, SER-301, and many others.
Microbiome Overview
Microbiome refers to the collection of microbes and their interaction with the human body. The microbiome plays an important role in human physiology and disease. The microbes and their interaction with the human body show the various aspects of human biology. The human body possesses a number of different species particularly bacteria and fungi which help in digesting food, preventing infections, and performing numerous life-supporting tasks. Microbes can also be harmful to their human hosts. Role of Microbiota in Health and Disease in Metabolic Disorders.
Microbiome Pipeline Therapies and Key Companies
-
Ferring pharmaceuticals: RBX 2660
-
Seres Therapeutics: SER-109
-
4D Pharma: Blautix
And many others
Scope of the PD-1 and PD-L1 Inhibitors Pipeline Report
-
Coverage: Global
-
Key Microbiome Companies: Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.
-
Key Microbime Pipeline Therapies: KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 , CTP-543, PF-06651600 and others.
Find out more about the PD-1 and PD-L1 Inhibitors treatment options in development @ Microbiome Clinical Trials
Table of Contents
Introduction
Executive Summary
Microbiome: Overview
-
Introduction
-
Mechanism of Action
-
Application
-
Limitation
-
Approved Therapies
Microbiome: In-depth Commercial Assessment
-
Microbiome Collaboration Analysis by Companies
Competitive Landscape
-
Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
-
Assessment by Product Type
-
Assessment by Stage and Product Type
-
Assessment by Route of Administration
-
Assessment by Stage and Route of Administration
-
Assessment by Molecule Type
-
Assessment by Stage and Molecule Type
Microbiome: Company and Product Profiles (Marketed Therapies)
JW Therapeutics
-
Company Overview
Relmacabtagene autoleucel
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Microbiome: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Registered)
-
Comparative Analysis
CARsgen
-
Company Overview
Zevorcabtagene autoleucel
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Mid-Stage Products (Phase II)
-
Comparative Analysis
Cartesian Therapeutics
-
Company Overview
Descartes 011
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Early Stage Products (Phase I)
-
Comparative Analysis
Autolus Therapeutics
-
Company Overview
AUTO-8
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Preclinical and Discovery Stage Products
-
Comparative Analysis
Sana Biotechnology
-
Company Overview
SG299
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Inactive Products
-
Comparative Analysis
Microbiome – Unmet needs
Microbiome – Market drivers and barriers
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services